Cynata Therapeutics Limited
CYYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.12 | -0.17 | 0.02 |
| FCF Yield | -20.95% | -5.26% | -9.97% | -25.57% |
| EV / EBITDA | -3.85 | -13.11 | -8.11 | -1.12 |
| Quality | ||||
| ROIC | -167.02% | -22.48% | -23.85% | -18.44% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 44.49% |
| Cash Conversion Ratio | 1.01 | 0.80 | 0.98 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.61% | 6.17% | -13.25% | 2.96% |
| Free Cash Flow Growth | -93.08% | 41.75% | -5.26% | 30.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.87 | 2.99 | 1.12 | 1.61 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -110.83 | 0.00 | -321.20 | -434.69 |